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The Wilms’ tumor 1 protein WT1 is a transcriptional
regulator that is involved in cell growth and dif-
ferentiation. The transcriptional corepressor BASP1
interacts with WT1 and converts WT1 from a tran-
scriptional activator to a repressor. Here, we demon-
strate that the N-terminal myristoylation of BASP1 is
required in order to elicit transcriptional repression
at WT1 target genes. We show that myristoylated
BASP1 binds to nuclear PIP2, which leads to the
recruitment of PIP2 to the promoter regions of
WT1-dependent target genes. BASP1’s myristoyla-
tion and association with PIP2 are required for the
interaction of BASP1 with HDAC1, which mediates
the recruitment of HDAC1 to the promoter and elicits
transcriptional repression. Our findings uncover a
role for myristoylation in transcription, as well as a
critical function for PIP2 in gene-specific transcrip-
tional repression through the recruitment of histone
deacetylase.INTRODUCTION
The Wilms’ tumor 1 protein WT1 plays a central role in develop-
ment and in both pediatric and adult cancers (Rivera and Haber,
2005; Hohenstein and Hastie, 2006; Huff, 2011). WT1 is a tran-
scriptional regulator that can either activate or repress transcrip-
tion (Roberts, 2005). We identified BASP1 (NAP-22, CAP-23) as
a WT1-binding protein that mediates its transcriptional repres-
sion activity (McKay et al., 1999; Carpenter et al., 2004). Several
previous studies showed that BASP1 is stoichiometrically
N-terminally myristoylated in several tissues (e.g., neuronal,
kidney, testis, and lymphoid) and cell lines, and specifically asso-
ciates with phosphatidylinositol 4,5-bisphosphate (PIP2) at the
cell membrane (Maekawa et al., 1994; Mosevitsky et al., 1997;
Takasaki et al., 1999; Laux et al., 2000; Terashita et al., 2002;
Mosevitsky, 2005; Epand, 2008; see Figure 1A for summary).
The interaction of BASP1 with PIP2 requires both the myristoyla-
tion motif and the N-terminal region of BASP1, which contains462 Cell Reports 2, 462–469, September 27, 2012 ª2012 The Authora conserved serine (residue 6) that can be phosphorylated by
protein kinase C (PKC) in vivo (Maekawa et al., 1994; Mosevitsky
et al., 1997; Kashihara et al., 2000;Mosevitsky, 2005). Phosphor-
ylation of this residue disrupts the interaction of BASP1 with
lipids (Peitzsch and McLaughlin, 1993; Mosevitsky et al., 1997;
Mosevitsky, 2005).
BASP1 is present in the nucleus, mediated by a functional
bipartite nuclear localization sequence (NLS) located between
residues 7 and 25, and localizes to the promoters of several
WT1 target genes (Carpenter et al., 2004; Green et al., 2009;
Essafi et al., 2011; Goodfellow et al., 2011; see Figure 1A for
summary). BASP1 also regulates other transcription factors,
and can inhibit cellular transformation induced by v-myc and
block the regulation of myc target genes (Hartl et al., 2009).
Moreover, BASP1 is downregulated in myc-transformed cells
and in a significant proportion of hepatocellular carcinomas
and leukemias through silencing of the BASP1 gene by methyla-
tion (Yeoh et al., 2002; Moribe et al., 2008; Hartl et al., 2009).
The mechanisms by which BASP1 acts as a transcriptional
corepressor are not known. In this study, we demonstrate that
the N-terminal myristoylation of BASP1 and the capacity of
BASP1 to interact with PIP2 are critical for its transcriptional
corepressor function with WT1. The BASP1-PIP2 interaction
promotes the recruitment of HDAC1 to the gene promoter
region, which then leads to transcriptional repression. Our
findings uncover a role for myristoylation in transcription and
a mode of gene-specific transcriptional repression through
nuclear lipids.
RESULTS AND DISCUSSION
Myristoylation of BASP1 Is Required for Its
Transcriptional Corepressor Function
BASP1 is myristoylated at its N terminus, which promotes
its interaction with PIP2 at the cell membrane (reviewed in
Mosevitsky, 2005; Epand, 2008; see Figure 1A for summary).
Mutation of BASP1 glycine-2 to alanine (G2A) completely
abrogates myristoylation, disrupts the interaction with PIP2,
and leads to membrane detachment (Takasaki et al., 1999;
Terashita et al., 2002; Epand, 2008; Korshunova et al., 2008).
Phosphorylation of BASP1 at serine-6 also causes the release
of BASP1 from lipids by creating an unfavorable electrostatics
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Figure 1. The Myristoylation of BASP1 Is Required for Its Transcriptional Repressor Activity
(A) Schematic of BASP1. The N-terminal 20 residues andmyristoylatedG2 are shown below, and the PKC site at S6, and NLS and PEST sequences are indicated.
pCDNA3 alone or driving the expression of wild-type BASP1, BASP1 G2A, or BASP1 S6D were transfected into M15 cells, and 48 hr later the nuclear (N) and
cytoplasmic (C) fractions were immunoblotted with the antibodies indicated. Lamin and b-tubulin are nuclear and cytoplasmic controls. M, myristoylation site;
NLS, nuclear localization sequence; P, phosphorylation site; S, sumoylation site.
(B) M15 cells (top) or U2OS cells (bottom) were transfected as in (A), and ChIP was performed with anti-BASP1 antibodies or control IgG. Primers to amplify the
WT1-binding regions of the JunB andCyclin E promoters were used in quantitative PCR (qPCR) to determine fold enrichment relative to a noncoding region. Error
bars are the standard deviation from the mean (SDM) of three independent experiments.
(C) M15 cells (top) or U2OS cells (bottom) were transfected as in (A) and 48 hr later, RNA and cDNAwere prepared. qPCRwas performed to detect GAPDH, JunB,
and Cyclin E mRNA. The data are presented relative to GAPDH mRNA and error bars denote the SDM of three independent experiments.
(D) M15 cells were transfected with pCDNA3 or pCDNA3 driving expression of BASP1 along with control, NMT1, or NMT2 siRNA. cDNAwas prepared 48 hr later,
and qPCR was performed to detect GAPDH, Cyclin E, and JunB mRNA. The graphs represent Cyclin E (top) and JunB (bottom) expression relative to GAPDH
(error bars are the SDM of three independent experiments). Below, simultaneously prepared whole-cell extracts were immunoblotted with the antibodies
indicated.
See also Figure S1.environment close to the myristoyl motif (Peitzsch and
McLaughlin, 1993; Mosevitsky et al., 1997). Thus, the phospho-
mimetic mutant BASP1 derivative S6D also leads to membrane
detachment (Mosevitsky, 2005). We hypothesized that a BASP1
mutant derivative that prevents myristoylation (G2A), or a mimicCelof phosphorylation of BASP1 (serine-6 [S6D]) would lead to
increased nuclear localization of BASP1. Mouse embryonic
kidney M15 cells were transfected with pcDNA3 or pcDNA3,
driving the expression of wild-type BASP1, BASP1 G2A, or
BASP1 S6D. An analysis of nuclear and cytoplasmic extractsl Reports 2, 462–469, September 27, 2012 ª2012 The Authors 463
demonstrated that both the prevention of BASP1 myristoylation
(G2A) and the use of the phosphomimetic S6D led to an increase
of the proportion of BASP1 in the nucleus (Figure 1A).
WT1 and BASP1 coimmunoprecipitate from nuclear extracts
of both M15 (Carpenter et al., 2004) and U2OS cells (Figure S1).
Therefore, we performed a chromatin immunoprecipitation
(ChIP) analysis to analyze the association of wild-type BASP1,
BASP1 G2A, or BASP1 S6D with the WT1-binding regions of
the JunB and Cyclin E promoters in either M15 cells or U2OS
cells. Consistent with the enhanced nuclear localization of
BASP1 G2A and BASP1 S6D compared with wild-type BASP1,
there was an increase in promoter localization of the mutant
BASP1 derivatives (Figure 1B). Surprisingly, however, when we
analyzed the expression of the endogenous JunB and Cyclin E
genes in either M15 cells or U2OS cells, we found that BASP1
G2A and BASP1 S6D were both significantly defective in tran-
scriptional repression compared with wild-type BASP1 (Fig-
ure 1C). These results suggest that myristoylation of BASP1
and the capacity for PIP2 binding are required for BASP1’s func-
tion as a WT1 transcriptional corepressor.
We sought to confirm and extend these findings by blocking
BASP1 myristoylation through ablation of N-myristoyltransfer-
ase (NMT) activity. Mammalian cells express two isoforms of
NMT, termed NMT1 and NMT2. M15 cells were transfected
with either pcDNA3 or the same vector, driving expression of
BASP1 along with either a control small interfering RNA (siRNA)
or siRNA directed to NMT1 or NMT2.Western blotting confirmed
successful NMT1 and NMT2 ablation by their respective siRNAs
(Figure 1D). As before, expression of wild-type BASP1 repressed
transcription of both the Cyclin E and JunB genes. However,
when expression of NMT1, but not NMT2, was ablated, the effect
of BASP1 expression on both genes was reduced. These data
independently confirm that myristoylation of BASP1 is required
for its transcriptional corepressor activity.
BASP1 Associates with Nuclear PIP2
It is well established that various phospholipids, including PIP2,
are present in the cell nucleus (Albi and Viola Magni, 2004;
Barlow et al., 2010; Keune et al., 2011). We therefore sought to
determine whether endogenous BASP1 colocalizes with PIP2
in the nucleus by using coimmunofluorescence. We used anti-
PIP2 antibodies in a protocol that was previously optimized
to specifically detect detergent-resistant PIP2 in the nucleus
(Osborne et al., 2001; Mortier et al., 2005). Both PIP2 and
BASP1 were detected in the nucleus of U2OS cells (Figure 2A),
and confocal microscopy revealed significant nuclear colocali-
zation (Figure 2B). To confirm that the anti-PIP2 antibodies
were recognizing PIP2, we treated the U2OS cells with neomycin
(2 mg/ml) for 12 hr prior to immunofluorescence with anti-PIP2
antibodies. Neomycin chelates PIP2 and was previously shown
to block its interaction with the same antibodies used in our
experiments (Osborne et al., 2001). Treatment of U2OS cells
with neomycin significantly reduced the nuclear signal with the
anti-PIP2 antibodies, confirming that they specifically re-
cognize phosphoinositides (Figure 2C). Comparable results
were obtained when we analyzed BASP1 and PIP2 localization
in MCF7 cells (Figure S2). To provide further evidence that
BASP1 interacts with nuclear PIP2, we performed immunopre-464 Cell Reports 2, 462–469, September 27, 2012 ª2012 The Authorcipitation with HeLa cell nuclear extracts. Anti-PIP2 immunopre-
cipitates contained BASP1 (Figure 2D), and dot-blotting con-
firmed that the anti-BASP1 immunoprecipitates contained PIP2
(Figure 2E). We sought to confirm these results by direct binding
of BASP1 from nuclear extracts to control agarose beads, or
agarose beads containing PIP2, or phosphatidylinositol 3,4,5
triphosphate (PIP3; Figure 2F). Nuclear BASP1 was retained by
the PIP2 beads but not by the PIP3 beads. Taken together,
the data in Figure 2 demonstrate that BASP1 interacts with
nuclear PIP2.
BASP1-Dependent Recruitment of PIP2 to the Promoter
of WT1 Target Genes
We next explored the functional role that PIP2 plays in BASP1-
dependent transcriptional repression. K562 cells express wild-
type WT1 but do not express BASP1, and thus the endogenous
WT1 acts primarily as a transcriptional activator (Goodfellow
et al., 2011). Introduction of BASP1 into K562 cells leads to the
repression of WT1 target genes via a WT1-dependent mecha-
nism that requires the recruitment ofBASP1 to the genepromoter
(Goodfellow et al., 2011). We therefore generated several K562
cell line derivatives that express either wild-type BASP1 or the
BASP1mutant derivatives aG2A (whichpreventsmyristoylation),
S6A (which prevents phosphorylation of BASP1 at Ser-6), S6D
(which mimics phosphorylation of Ser-6), and mNLS (K7A:K9A,
which abolishes nuclear localization of BASP1, as we previously
demonstrated; Goodfellow et al., 2011). We then prepared cDNA
from the cell lines andmeasured the expression of theWT1 target
genes amphiregulin (AREG),Ets-1, VitaminD receptor (VDR), and
JunB, along with Bax as a control non-WT1 target gene (Fig-
ure 3A). As we reported in a recent study (Goodfellow et al.,
2011), expression of wild-type BASP1 in K562 cells resulted in
reduced expression of AREG, Ets-1, VDR, and JunB, but not
Bax. In addition, as we also noted in that study, disruption of
the nuclear localization signal of BASP1 (mNLS) ablated BASP1
corepressor function. Consistent with the data in Figure 1,
expression of BASP1 G2A failed to repress expression of any of
the WT1 target genes. BASP1 S6A, which retains PIP2-binding
capacity, repressed transcription of the WT1 target genes. As
before (Figure 1), BASP1 S6D failed to act as a transcriptional
repressor.
To determine whether the transcriptional effects we observed
above were PIP2 dependent, we immunoprecipitated wild-type
BASP1 or BASP1 G2A from K562 cell extracts and performed
a dot-blot analysis with anti-PIP2 antibodies. Although both
wild-type BASP1 and BASP1 G2A were equivalently immuno-
precipitated, PIP2 was only detected in the precipitate from cells
expressing wild-type BASP1 (Figure 3B). Moreover, whereas
wild-type BASP1 from nuclear extract was retained by PIP2-
agarose beads (but not PIP3-agarose beads) in pull-down
assays (as in Figure 1F), BASP1 G2A was not (Figure 3C). These
results confirm that myristoylation of BASP1 is required for its
interaction with PIP2, and that this interaction is specific to PIP2.
We next performed ChIP assays with vector control K562 cells
and K562 cells expressing wild-type BASP1 or BASP1 G2A (Fig-
ure 3D). WT1 occupied the AREG, Ets-1, VDR, and JunB pro-
moter regions in both vector control K562 cells and BASP1-ex-
pressing K562 cells. In addition, K562 cells expressing BASP1s
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Figure 2. BASP1 Associates with Nuclear PIP2
(A) U2OS cells were subjected to coimmunofluorescence with rabbit BASP1 antibodies and mouse PIP2 antibodies. Control anti-mouse (m) and anti-rabbit (r)
antibodies are shown in the bottom row.
(B) As in (A) except that confocal microscopy was used to visualize nuclear BASP1 and PIP2.
(C) U2OS cells were mock-treated or treated with 2 mg/ml neomycin for 24 hr prior to immunofluorescence with either BASP1 or PIP2 antibodies.
(D) HeLa nuclear extract was subjected to immunoprecipitation with control IgG or PIP2 antibodies, and the samples were immunoblotted with BASP1 anti-
bodies.
(E) HeLa nuclear extract was subjected to immunoprecipitation with control IgG or BASP1 antibodies, and the samples were immunoblotted with BASP1
antibodies or dot-blotted with PIP2 antibodies.
(F) Nuclear extract derived from K562 cells stably transfected to express wild-type BASP1 was incubated with control agarose beads or beads containing equal
amountsof eitherPIP2orPIP3.After thebeadswerewashed, theboundproductsweresubjected to immunoblottingwithBASP1antibodies. I, input nuclearextract.
See also Figure S2.G2A also retained recruitment of WT1 at the promoters. ChIP
analysis with anti-PIP2 antibodies revealed that PIP2 showed
enhanced recruitment to all four promoters in K562cells express-
ing wild-type BASP1 when compared with the vector control
K562 cells. Thus, BASP1-PIP2 complexes are recruited along
with WT1 to the promoters. Moreover, although BASP1 G2A is
present at the promoters along with WT1, it failed to recruit
PIP2 above the level observed in the vector control K562 cells.
Taken together, these data demonstrate that PIP2-bound
BASP1 is recruited to the promoter of a WT1 target gene, and
that myristoylation of BASP1 is required for inclusion of PIP2 in
the complex.
We previously showed that WT1 and BASP1 transcriptionally
cooperate to divert the phorbol ester-induced differentiation
program of K562 cells to an arborized cell type with neuronal
characteristics (Goodfellow et al., 2011). We therefore treated
control K562 cells or K562 cells stably expressing either wild-Celtype BASP1 or BASP1 G2A with phorbol myristyl acetate
(PMA) and allowed the cells to differentiate over 3 days. As
before, K562 cells expressing wild-type BASP1 exhibited an
arborized phenotype (Figure 3E). Consistent with the lack of
WT1 corepressor activity, BASP1 G2A failed to support signifi-
cant arborization of K562 cells.
Myristoylation-Dependent Association of BASP1 with
Histone Deacetylase
BASP1 has been associated with localized histone modification
at the Wnt4 gene promoter (Essafi et al., 2011). We therefore
sought to determine whether BASP1 uses histone deacetylases
as part of its transcriptional corepressor function. HeLa cell
nuclear extract was subjected to immunoprecipitation with
anti-BASP1 antibodies, and the presence of histone deacetylase
activity was determined (Figure 4A). BASP1 immunoprecipitates
contained significantly more histone deacetylase activity thanl Reports 2, 462–469, September 27, 2012 ª2012 The Authors 465
AB
C
D
E
Figure 3. BASP1 Recruits PIP2 to Promoter-Bound WT1
(A) Vector controlK562cells (V) orK562cell linederivativesexpressingwild-typeBASP1 (wt) or themutantderivativesG2A,S6A,mNLS (K7A:K9A),andS6Dwereused
topreparecDNA.Expressionof theWT1 targetgenesAREG,Ets-1,VDR,JunB, and thenon-WT1 targetgeneBaxwasanalyzed incomparisonwithGAPDH. Errorbars
are the SDM of three independent experiments; *p < 0.05 by Student’s t test. Immunoblotting confirmed that the BASP1 derivatives are equivalently expressed.
(B) Immunoprecipitation of extracts derived from K562 expressing wild-type BASP1 or BASP1 G2A was performed with BASP1 antibodies, and the immuno-
precipitates were either immunoblotted with BASP1 antibodies (above) or dot-blotted with PIP2 antibodies.
(C) Nuclear extract derived from K562 cells expressing either wild-type BASP1 or the G2A mutant derivative were incubated with control, PIP2, or PIP3 agarose
beads. Stably bound products were subjected to immunoblotting with BASP1 antibodies.
(D) ChIP was performed with vector control K562 cells (V) or K562 cells expressing wild-type BASP1 or the mutant BASP1 derivative G2A with control IgG, WT1,
BASP1, and PIP2 antibodies. The data are presented as fold enrichment at the AREG, Ets-1, VDR, and JunB promoter regions compared with a control genome
region. Error bars are the SDM of three independent experiments; *p < 0.05 by Student’s t test.
(E) Vector control K562 cells (V) or K562 cells expressing either wild-type BASP1 (wt BASP1) or the mutant derivatives G2A were mock-treated (Ctrl) or treated
with 100 nM PMA and imaged 72 hr later. Below, quantitation of the percentage of arborized cells is shown (error bars are the SDM of three independent
experiments; *p < 0.05 by Student’s t test).
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Figure 4. Myristoylated BASP1 Recruits Functional HDAC1 to the
Promoter
(A) BASP1 antibodies or control IgG were used in immunoprecipitation with
HeLa nuclear extracts and subjected to histone deacetylase assay. Error bars
are the SDM of three independent experiments; *p < 0.05 by Student’s t test.
(B) BASP1 was immunoprecipitated as in (A) and immunoblotted with the
HDAC antibodies indicated.
(C) BASP1 was immunoprecipitated from K562 cells expressing wild-type
BASP1 or BASP1 G2A, and the samples were immunoblotted with BASP1
(top) or HDAC1 antibodies. a-IgG are control antibodies.
(D) As in (C) except that anti-WT1 antibodies were used for immunoprecipi-
tation, and HDAC1 and BASP1 were detected by immunoblotting (above) or
anti-CapZ antibodies were used for immunoprecipitation followed by immu-
noblotting with BASP1 antibodies.
(E) Nuclear extracts derived from K562 cell expressing either wild-type BASP1
or BASP1 G2A were incubated with control agarose beads or beads con-
taining PIP2. The bound fraction was immunoblotted with the antibodies
indicated.
Celcontrol immunoprecipitates, and this activity was inhibited by
sodium butyrate, which predominantly inhibits class 1 and 2
HDACs. Immunoblotting of BASP1 immunoprecipitates with
a battery of HDAC antibodies revealed that BASP1 specifically
associated with HDAC1 (Figure 4B). To determine whether this
BASP1-HDAC1 association required the BASP1-PIP2 inter-
action, we immunoprecipitated BASP1 from nuclear extracts
derived from K562 cells that express either wild-type BASP1 or
BASP1 G2A (which is defective in myristoylation). Whereas the
immunoprecipitates of wild-type BASP1 contained HDAC1, the
immunoprecipitates of BASP1 G2A did not (Figure 4C). These
results indicate that the BASP1-PIP2 interaction is required for
the association of BASP1 with HDAC1.
Our results suggest that BASP1 provides a link between WT1
and HDAC1, and that this would require the myristoylation of
BASP1. In support of this hypothesis, we found that anti-WT1
antibodies specifically coimmunoprecipitate HDAC1 from K562
cells stably expressing wild-type BASP1, but not from K562 cells
expressing BASP1 G2A (Figure 4D). In contrast, and consistent
with the fact that BASP1 G2A localizes to the promoter regions
of WT1-responsive genes (Figure 3D), we found that anti-WT1
antibodies coimmunoprecipitated both wild-type BASP1 and
BASP1 G2A (Figure 4D). The actin-capping protein CapZ was
previously shown to bind to BASP1 independently of myristoyla-
tion status (Odagaki et al., 2009), and consistent with this we
found that CapZ antibodies coimmunoprecipitated both wild-
type BASP1 and BASP1 G2A (Figure 4D, lower panel). Taken
together, the data in Figure 4D suggest that WT1 interacts with
HDAC1 through myristoylation of BASP1 and that BASP1 G2A
is specifically defective in interacting with HDAC1.
We next determined whether WT1 and HDAC1 interact with
PIP2 via myristoylated BASP1. HDAC1 and WT1 were recruited
to PIP2-agarose beads only from K562 cell extracts containing
wild-type BASP1 and not BASP1 G2A (Figure 4E). RNA poly-
merase II (RNA pol II) was included as a control protein that binds
to PIP2 independently of BASP1. These results suggest the
formation of a complex among WT1, BASP1, and HDAC1 that
is dependent on the myristoylation of BASP1 and the inclusion
of PIP2 in the complex.
We next performed ChIP assays to determine whether the
myristoylation of BASP1 is required for the recruitment of
HDAC1 to the promoters of the AREG, Ets-1, VDR and JunB
genes, and whether this in turn affects histone H3K9 acetylation
status at each promoter. Vector control K562 cells or K562 cell
line derivatives expressing either wild-type BASP1 or BASP1
G2A were subjected to ChIP with control antibodies, anti-
HDAC1, or anti-acetyl-H3K9 antibodies. Compared with the
vector control cells, cells expressing wild-type BASP1 showed
an increase in HDAC1 recruitment to all four promoters and
a concomitant reduction in H3K9 acetylation (Figure 4F). In
contrast, cells expressing BASP1 G2A did not show enhanced(F) ChIP was performedwith vector control K562 cells or K562 cells expressing
wild-type BASP1 (wt BASP1) or the mutant BASP1 derivative G2A with control
IgG, HDAC1, or acetyl H3K9 antibodies. The data are presented as fold
enrichment at the AREG, Ets-1, VDR, and JunB promoter regions compared
with a control genome region. Error bars are the SDM of three independent
experiments; *p < 0.05 by Student’s t test.
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HDAC1 recruitment compared with control cells, and also did
not result in a significant reduction in histone H3K9 acetylation.
Thus, the PIP2-dependent association of BASP1 with HDAC1
leads to a repressive chromatin state at the AREG, Ets-1, VDR,
and JunB promoters.
It is well established that PIP2 is present in the nucleus, where
it has been shown to associate with RNA pol II and to regulate
the activity of ATP-dependent chromatin-remodeling activities
(Zhao et al., 1998; Osborne et al., 2001; Rando et al., 2003;
Shen et al., 2003; Steger et al., 2003). Our findings demonstrate
that PIP2 associates with transcription factors at the promoter to
direct a gene-specific role in transcriptional regulation.
How the BASP1-PIP2 interaction drives association with
HDAC1 is not clear. However, other phospholipids have been
shown to regulate protein complexes that possessHDACactivity
(Gozani et al., 2003; Hait et al., 2009; Han and Emr, 2011). There-
fore, PIP2may be directly involved in the interaction with HDAC1
rather than acting exclusively on BASP1 conformation. Our find-
ings suggest that myristoylation provides an interface between
nuclear lipids and the chromatin-remodeling machinery.
Because BASP1 can also regulate the activity of other transcrip-
tion factors, such as myc, this myristoylation- and PIP2-depen-
dent mechanism of transcriptional repression will likely also
apply to other DNA-binding transcriptional regulators.
EXPERIMENTAL PROCEDURES
Tissue Culture, Immunofluorescence, Plasmids, and Transfection
BASP1 mutant derivatives were generated using the QuikChange muta-
genesis kit (QIAGEN). M15 and U2OS cells were cultured in Dulbecco’s modi-
fied Eagle’s medium, and K562 cells were cultured in RPMI medium. Stable
K562 cell line derivatives were generated as described previously (Goodfellow
et al., 2011). Cells were transfected with Lipofectamine 2000 (Invitrogen) or
Effectene (QIAGEN). Immunofluorescence was performed as previously
described (Carpenter et al., 2004). BASP1 antibodies were described previ-
ously (Carpenter et al., 2004). Antibodies anti-WT1 (C-19), anti-GAPDH
(6C5), anti-CapZ (C-7), and anti-Lamin A/C (N-18) were obtained from Santa
Cruz Biotechnology. Anti-NMT1 (ab84666), anti-NMT2 (ab102473), anti-
H3K9Ac (ab10812), anti-PIP2 (ab11039), anti-pol II (ab5408), anti-b-tubulin
(ab6160), and HDAC1 (ab19485) were obtained from Abcam. HDAC1-4
antibodies (sampler kit 9928) were obtained from Cell Signaling.
Protein, mRNA, and ChIP Analysis
Nuclear/cytoplasmic extracts were prepared as described previously
(Hartkamp et al., 2010). Total RNA was prepared using the QIAGEN RNeasy
kit, and cDNA was prepared using the Bio-Rad cDNA synthesis kit. ChIP
assays were performed as described previously (Hartkamp et al., 2010).
Histone deacetylase activity was assayed with the use of a kit from Millipore.
siRNAs to mouse NMT1 and NMT2 were obtained from QIAGEN. PIP2 and
PIP3 agarose beads were purchased from Echelon Biosciences, and binding
assays were performed as previously described (Lewis et al., 2011). For the
primers used in this study, see Extended Experimental Procedures.
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